Form 4: Twist Bioscience Director Sells 7,044 Shares
Insider Transaction Report
Twist Bioscience Director Jan Johannessen reported the sale of 7,044 shares of common stock at $24.77 per share.
Summary
- Jan Johannessen, a Director at Twist Bioscience Corp (TWST), sold 7,044 shares of common stock.
- The transaction occurred on November 18, 2025, at a price of $24.77 per share.
- Following this sale, Jan Johannessen beneficially owns 14,859 shares of Twist Bioscience common stock.
- The Form 4 filing was signed by Kendra Fox as Attorney-in-Fact for Jan Johannessen on November 20, 2025.
- A Power of Attorney document, dated May 8, 2025, authorizes specific individuals to execute and file SEC Forms 3, 4, and 5 on behalf of Jan Johannessen.
Sentiment
Score: 4
Explanation: A director selling a portion of their holdings can be perceived as a minor negative signal, although such transactions can occur for personal financial planning reasons and do not necessarily reflect a negative outlook on the company's future.
Positives
- The transaction was executed at a specific market price, indicating liquidity for the shares.
- The Power of Attorney ensures compliance with SEC filing requirements for the director.
Negatives
- A director selling shares can sometimes be interpreted as a lack of confidence in the company's short-term prospects, though this is not always the case.
Future Outlook
na
Industry Context
This Form 4 filing reports an individual insider transaction and does not provide broader industry context. Insider sales are a routine part of market activity, but the specific implications depend on the individual's role, the size of the sale relative to their holdings, and overall market conditions for the biotechnology sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization of Attorney-in-Fact | Jan Johannessen granted Power of Attorney to Dennis Cho, Judy Yan, and Kendra Fox to execute and file SEC Forms 3, 4, and 5 on his behalf, ensuring compliance with Section 16(a) of the Securities Exchange Act of 1934. | 2025-05-08 | Streamlines the process for insider reporting and ensures timely compliance with regulatory requirements for the director. |
Stakeholder Impact
- Shareholders: May view the director's sale as a minor negative signal, potentially influencing short-term sentiment.
Key Dates
| Date | Description |
|---|---|
| 2025-05-08 | Execution date of the Power of Attorney document by Jan Johannessen. |
| 2025-11-18 | Date of the reported transaction where Jan Johannessen sold common stock. |
| 2025-11-20 | Date the Form 4 filing was signed by the Attorney-in-Fact. |
Recommendation
holdA single Form 4 filing reporting a director's sale of shares, while noteworthy, typically does not provide sufficient information to warrant a strong 'buy' or 'sell' recommendation. Such transactions can be for personal liquidity or diversification reasons. Investors should consider this information in conjunction with the company's broader financial performance, strategic outlook, and overall market conditions before making investment decisions. A 'hold' recommendation reflects the need for further analysis beyond this specific transaction.
Keywords
Twist Bioscience, TWST, Insider Trading, Form 4, Director Sale, Stock Transaction, Jan Johannessen, SEC Filing, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.